A 12-Week Treatment, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease.

Trial Profile

A 12-Week Treatment, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INLIGHT-1
  • Sponsors Novartis
  • Most Recent Events

    • 17 Mar 2012 This trial is recruiting in France and has been discontinued in England, Denmark and Lithuania.
    • 17 Mar 2012 Additional locations (Denmark, England, France, Germany, Lithuania,) added as reported by European Clinical Trials Database.
    • 17 Mar 2012 Planned number of patients changed from 416 to 450 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top